Tomaru A, Takeda Morishita M, Maeda K, Banba H, Takayama K, Kumagai Y, et al. Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects. Drug Metab Pharmacokinet. 2015;30:221-6 pubmed publisher

Hosny K, Hassan A. Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation. Int J Pharm. 2014;475:191-7 pubmed publisher

Petković F, Blaževski J, Momcilovic M, Timotijevic G, Zocca M, Mijatovic S, et al. Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2013;259:55-65 pubmed publisher

Hobbs C, Tanaka T, Muratova O, Van Vliet J, Borkowsky W, Williamson K, et al. HIV treatments have malaria gametocyte killing and transmission blocking activity. J Infect Dis. 2013;208:139-48 pubmed publisher

Park K. Transport of nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166:195 pubmed publisher

Harada S, Yoshimura K, Yamaguchi A, Boonchawalit S, Yusa K, Matsushita S. Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro. J Gen Virol. 2013;94:933-943 pubmed publisher

Beloqui A, Solinís M, Gascón A, del Pozo Rodríguez A, des Rieux A, Préat V. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166:115-23 pubmed publisher

Santos L, Vitório B, Branquinha M, Pedroso E Silva C, Santos A, D Ávila Levy C. Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients. J Antimicrob Chemother. 2013;68:348-53 pubmed publisher

Rasmussen L, Mathiesen E, Kronborg G, Pedersen C, Gerstoft J, Obel N. Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS ONE. 2012;7:e44575 pubmed publisher

Brunet C, Reliquet V, Jovelin T, Venisse N, Winer N, Bui E, et al. Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort. Med Mal Infect. 2012;42:421-8 pubmed publisher

Mojic M, Mijatovic S, Maksimovic Ivanic D, Miljkovic D, Stosic Grujicic S, Stankovic M, et al. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. Mol Pharmacol. 2012;82:700-10 pubmed

Kuo Y, Wang C. Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia. Colloids Surf B Biointerfaces. 2013;101:101-5 pubmed publisher

Sidrim J, Perdigão Neto L, Cordeiro R, Brilhante R, Leite J, Teixeira C, et al. Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans. Can J Microbiol. 2012;58:932-6 pubmed publisher

Esposito V, Manente L, Lucariello A, Perna A, Viglietti R, Gargiulo M, et al. Role of FAP48 in HIV-associated lipodystrophy. J Cell Biochem. 2012;113:3446-54 pubmed publisher

Donia M, Mangano K, Fagone P, De Pasquale R, Dinotta F, Coco M, et al. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. Oncol Rep. 2012;28:682-8 pubmed publisher

Stefanidou M, Herrera C, Armanasco N, Shattock R. Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention. Antimicrob Agents Chemother. 2012;56:4381-90 pubmed publisher

Liang Z. Perspectives on addressing ionization matrix effects in LC-MS bioanalysis. Bioanalysis. 2012;4:1227-34 pubmed publisher

Wang Z, Pal D, Mitra A. Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir. J Pharm Sci. 2012;101:3199-213 pubmed publisher

Ramana L, Sharma S, Sethuraman S, Ranga U, Krishnan U. Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity. Int J Pharm. 2012;431:120-9 pubmed publisher

Palefsky J. HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges. AIDS. 2012;26:1035-6 pubmed publisher

Wenderfer S. Can inhibition of proteasomes or NF-kappaB help control idiopathic nephrotic syndrome?. Nephrol Dial Transplant. 2012;27:1698-701 pubmed publisher

Davis D, Soule E, Davidoff K, Daniels S, Naiman N, Yarchoan R. Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing. Antimicrob Agents Chemother. 2012;56:3620-8 pubmed publisher

Coppo R, Camilla R, Porcellini M, Peruzzi L, Gianoglio B, Amore A, et al. Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study. Nephrol Dial Transplant. 2012;27:1902-10 pubmed publisher

Maksimovic Ivanic D, Stosic Grujicic S, Nicoletti F, Mijatovic S. Resistance to TRAIL and how to surmount it. Immunol Res. 2012;52:157-68 pubmed publisher

Mojic M, Mijatovic S, Maksimovic Ivanic D, Dinić S, Grdovic N, Miljkovic D, et al. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. Cell Cycle. 2012;11:1174-82 pubmed publisher

Martin R, Butterworth A, Gardiner D, Kirk K, McCarthy J, Skinner Adams T. Saquinavir inhibits the malaria parasite's chloroquine resistance transporter. Antimicrob Agents Chemother. 2012;56:2283-9 pubmed publisher

Manente L, Lucariello A, Costanzo C, Viglietti R, Parrella G, Parrella R, et al. Suppression of pre adipocyte differentiation and promotion of adipocyte death by anti-HIV drugs. In Vivo. 2012;26:287-91 pubmed